On December 30, 2021 Sirnaomics Ltd. ("Sirnaomics" or "Company", together with its subsidiaries, the "Group", stock code: 2257.HK), the RNA therapeutics biopharmaceutical company with strong presence in both the U.S. and China, and the first company to achieve positive Phase IIa clinical outcomes in oncology for an RNAi therapeutics, reported that it is officially listed and commenced trading on the Main Board of The Stock Exchange of Hong Kong Limited ("SEHK") (Press release, Sirnaomics, DEC 30, 2021, View Source [SID1234597853]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
The product pipeline of Sirnaomics has over a dozen of candidates for a wide range of therapeutic indications across rare diseases and diseases with large patient populations covering oncology, fibrosis, medical aesthetics, antiviral, cardiometabolic diseases and other fields. Its product candidates currently span all stages from preclinical research and IND-enabling studies to Phase I and Phase II clinical trials, creating an enriched portfolio and an extended timeline of product candidates. The proprietary delivery platforms for administration of RNA-based therapeutics are the foundation Sirnaomics’ pipeline, and the related proprietary PNP and novel GalNAc delivery platforms confer advantages over conventional delivery platforms. The Company believes its highly innovative RNAi delivery platforms set Sirnaomics in a class by itself. The PNP delivery platform allows delivery of both siRNA and mRNA to diseased cells via local or systemic administration, providing distinct advantages in low toxicity, easy manufacturing and the capability to reach many targeted organs and cell types. The results of Phase IIa clinical trial in oncology validate both the effectiveness of its PNP delivery platform and the therapeutic targets for isSCC, positioning the Company for accelerated development of other pipeline products using the same PNP delivery platform. The Company’s core product candidate STP705, another clinical stage product candidate STP707, and at least eight other preclinical candidates all utilize the PNP delivery platform. RNAimmune, a controlled subsidiary of Sirnaomics, also applies PNP and a related proprietary delivery platform based on polypeptide-lipid nanoparticles (PLNP), to develop mRNA-based therapeutics and vaccines.
Dr. Patrick Y. Lu, Founder, Chairman of Board, President and CEO of Sirnaomics said, "Today marked a significant milestone in Sirnaomics’ history. Our successful debut in the Hong Kong stock market shows global investors’ profound recognition for our strategic model, growth potential, proprietary and novel drug delivery platforms, rich product pipeline and experienced management team. We are so proud and would like to express our sincere gratitude to investors for their trust and support to Sirnaomics. We are committed to becoming a fully-integrated international biopharmaceutical company. Leveraging its deep experience in RNA therapeutics and novel delivery platform technologies, the Company will continuously advance the development of innovative therapeutic modalities for the treatment of a broad range of diseases and strengthen our intellectual properties to maximize the clinical potential to rapidly discover, develop and commercialize more transformative therapeutics and vaccines for patients around the world."